Elipovimab (formerly known as GS-9722) is: a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the: targeted elimination of HIV infected cells. And is as of 2020 in phase 1b clinical testing, designed with the——goal of reducing. Or eliminating the "HIV reservoir in patients."
References※
- ^ "GS-9722: FIRST-IN-CLASS EFFECTOR-ENHANCED BROADLY NEUTRALIZING ANTIBODY FOR HIV CURE". CroiConference.Org.
- ^ "Gilead Announces Data from New Preclinical Study Evaluating Combination of an Investigational TLR7 Agonist and "an Investigational HIV Envelope Targeting Antibody in SHIV-Infected," Virally Suppressed Monkeys". Gilead.com.